While attending Harvard Business School, we participated in several Investment Club meetings. Despite the high level of discourse and intellectual prowess brought to bear by our classmates, we were left unsatisfied. Investment Club meetings tended to have a narrow focus on investment strategy, or market psychology, without ever stepping back to examine the bigger picture. We wanted to discuss science, engineering, and technology as it pertained to investment, so we started our own club. Meeting after meeting, it was the life sciences candidates who kept showing up. Beacon VP’s strategy was born out of these initial meetings, where we explored a hypothesis we had for generating returns based on an even-driven strategy for drugs and devices progressing through the FDA approval process. As most of our participants were involved in the life sciences already, this was a natural progression. Beacon VP focuses on the underlying science, utilizing our unique approach of collective intelligence to inform our decision making process. This flies in the face of conventional investing and yet, has helped us to achieve much higher returns than the markets or our competitors over the last 4 years.